Name and surname:
|
prof. MUDr. Matej Samoš, PhD.
|
Document type:
|
Research/art/teacher profile of a person
|
The name of the university:
|
Comenius University Bratislava
|
The seat of the university:
|
Šafárikovo námestie 6, 818 06 Bratislava
|
III.a - Occupation-position | III.b - Institution | III.c - Duration |
---|---|---|
Professor | Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava | 2022 - |
Associate Professor | Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava | 2019 - 2022 |
Assistant | Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava | 2015 - 2019 |
Internal PhD. Student | Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava | 2011 - 2015 |
IV.a - Activity description, course name, other | IV.b - Name of the institution | IV.c - Year |
---|---|---|
Specialisation in Internal Medicine | Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava | 2018 |
Scientific Qualification IIa | Slovac Academy of Sciences in Bratislava | 2021 |
Specialisation in Cardiology | Faculty of Medicine, P.J. Šafárik University in Košice | 2021 |
V.1.a - Name of the profile course | V.1.b - Study programme | V.1.c - Degree | V.1.d - Field of study |
---|---|---|---|
Propedeutics of Internal Medicine 1,2 | General Medicine | I.+II. | General Medicine |
Internal Medicine 1 - 5 | General Medicine | I.+II. | General Medicine |
Propedeutics of Internal Medicine | Dentistry, Dental Medicine | I.+II. | Dentistry, Dental Medicine |
Internal Medicine 1 - 4 | Dentistry | I.+II. | Dentistry, Dental Medicine |
Internal Medicine 1,2 | Internal Medicine | III. | General Medicine |
V.5.a - Name of the course | V.5.b - Study programme | V.5.c - Degree | V.5.d - Field of study |
---|---|---|---|
Diploma Thesis Semminar 1-3 | General Medicine | I.+II. | General Medicine |
Samoš M, Šimonová R, Kovář F, Duraj L, Fedorová J, Galajda P, Staško J, Fedor M, Kubisz P, Mokáň M. Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis. Am J Emerg Med 2014; 32: 461 - 465.
Samoš M, Stančiaková L, Ivanková J, Staško J, Kovář F, Dobrotová M, Galajda P, Kubisz P, Mokáň M. Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation. J Thromb Thrombolysis 2015; 39: 95 - 100.
Samoš M, Bolek T, Ivanková J, Stančiaková L, Kovář F, Galajda P, Kubisz P, Staško J, Mokáň M. Heparin-induced Thrombocytopenia Presenting With Deep Venous Thrombosis and Pulmonary Embolism Successfully Treated With Rivaroxaban: Clinical Case Report and Review of Current Experiences. J Cardiovasc Pharmacol 2016; 68: 391 - 394.
Bolek T, Samoš M, Stančiaková L, Ivanková J, Škorňová I, Staško J, Galajda P, Kubisz P, Mokáň M. The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. Am J Ther 2019; 26: e308 - e313.
Samoš M, Bolek T, Stančiaková L, Škorňová I, Ivanková J, Kovář F, Galajda P, Kubisz P, Staško J, Mokáň M. Does type 2 diabetes affect the on-treatment levels of direct oral anticoagulants in patients with atrial fibrillation? Diabetes Res Clin Pract 2018; 135: 172 - 177.
Samoš M, Bolek T, Ivanková J, Stančiaková L, Kovář F, Galajda P, Kubisz P, Staško J, Mokáň M. Heparin-induced Thrombocytopenia Presenting With Deep Venous Thrombosis and Pulmonary Embolism Successfully Treated With Rivaroxaban: Clinical Case Report and Review of Current Experiences. J Cardiovasc Pharmacol 2016; 68: 391 - 394.
Bolek T, Samoš M, Stančiaková L, Ivanková J, Škorňová I, Staško J, Galajda P, Kubisz P, Mokáň M. The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. Am J Ther 2019; 26: e308 - e313.
Samoš M, Bolek T, Stančiaková L, Škorňová I, Ivanková J, Kovář F, Galajda P, Kubisz P, Staško J, Mokáň M. Does type 2 diabetes affect the on-treatment levels of direct oral anticoagulants in patients with atrial fibrillation? Diabetes Res Clin Pract 2018; 135: 172 - 177.
Samoš M, Bolek T, Stančiaková L, Škorňová I, Bánovčin P Jr, Kovář F, Staško J, Galajda P, Kubisz P, Mokáň M. Anti-Xa activity in oral factor Xa inhibitor-treated patients with atrial fibrillation and a higher risk of bleeding: a pilot study. Blood Coagul Fibrinolysis 2018; 29: 369 - 373.
Samoš M, Bolek T, Škorňová I, Benko J, Staško J, Kubisz P, Galajda P, Mokán M. Apixaban: a novel agent to treat heparin induced thrombocytopenia and to prevent embolism in patient with atrial fibrillation after multiple valve replacement? J Thromb Thrombolysis 2019; 48: 619 - 622.
Chan, N. C. - Coppens, M. - Hirsh, J. - Ginsberg, J. S. - Weitz, J. I. - Vanassche, T. - Douketis, J. D. - Schulman, S. - Eikelboom, J. W.: Journal of Thrombosis and Haemostasis, roč. 13, č. 3, 2015, s. 353-359 - SCI ; SCOPUS
Douketis, J. D. - Wang, G. - Chan, N. - Eikelboom, J. W. - Syed, S. - Barty, R. - Moffat, K. A. - Spencer, F. A. - Blostein, M. - Schulman, S.: Journal of Thrombosis and Haemostasis, roč. 14, č. 1, 2016, s. 89-97 - SCI ; SCOPUS
Warkentin, T. E. - Pai, M. - Linkins, L. A.: Blood, roč. 130, č. 9, 2017, s. 1104-1113 - SCI ; SCOPUS
Wang, N. - Chen, L. - Li, N. - Xu, G. - Qi, F. - Zhu, L. - Liu, W.: Scientific Reports, roč. 10, č. 1, 2020, čl. č. 9717 - SCI ; SCOPUS
Shin, H. J. - Boo, G. - Na, H. S.: Journal of Anesthesia, roč. 35, č. 5, 2021, s. 633-637 - SCI ; SCOPUS
APVV 16-00-20 Specific laboratory monitoring of platelets reactivity in patients with acute myocardial infarction treated by new antagonists of P2Y12 receptors (Co-Investigator).
VEGA 1/0549/19 Applications of results of DNA analyse and microRNA detection in primary and secondary proplylaxis of thromboembolic complications in patients with sticky platelet syndrome (Co-Investigator).
VEGA 1/0090/20 (2020 – 2022) New trends in treatment and new markers of progression of chronic heart disease with preserved ejection function im patients with type 2 diabetes mellitus. Research of risk factors of chronic heart failure with preserved ejection fraction in patients with obesity and type 2 diabetes mellitus. (Principal Investigator).
ITMS 2014+: 313011V344 European Structural and Investment Funds Long-term strategic research of prevention, intervention and mechanisms of obesity and its comorbidities. Activity – Mechanisms and markers of obesity and its comorbidities – research of microRNA as biomarkers. (Co-investigator).
VII.a - Activity, position | VII.b - Name of the institution, board | VII.c - Duration |
---|---|---|
Editorial Board Member | Frontiers in Endocrinology | 2020 - |
Editorial Board Member | Forum Diabetologicum | 2022 - |
Member of Academy of Postgraduate Education | European Federation of Internal Medicine (EFIM) | 2021 - |
Editorial Board Member | American Journal of Therapeutics | 2023 - |
Guest Editor | Pharmaceuticals | 2023 - |
Expert in Internal Medicine and Cardiology